On June 8, 2026 Nurix Therapeutics, Inc. (Nasdaq: NRIX) reported a global collaboration with Roche (SIX: RO, ROP; OTCQX: RHHBY) to develop and commercialize bexobrutideg, a potential best-in-class oral degrader of Bruton’s tyrosine kinase (BTK). The partnership brings together Nurix’s pioneering expertise in targeted protein degradation and Roche’s proven portfolio of B-cell targeted therapies and global clinical and commercial infrastructure. The collaboration encompasses a comprehensive clinical development plan spanning malignant hematology, immunology and neurology intended to explore the full clinical potential of BTK degradation across diverse patient populations. In addition to executing the previously disclosed pivotal Phase 2 and Phase 3 trials in CLL, the collaboration plans to pursue multiple label-enabling studies across a range of malignant hematology indications as monotherapy and in combination regimens and to expand development into immune-mediated diseases, including Phase 2 trials in MS and CSU.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Partnering with Roche, a world leader in the treatment of B-cell malignancies, positions Nurix to fully realize the potential of bexobrutideg across multiple indications in oncology, immunology and neurology," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. "We believe Roche is the ideal partner to help translate the promise of targeted protein degradation into meaningful impact for patients worldwide. With a co-development, co-commercialization structure in the U.S., this collaboration is a major step in Nurix’s evolution toward becoming a fully integrated biotechnology company with the capabilities to advance and ultimately commercialize transformative medicines in multiple therapeutic areas."

Levi Garraway, Roche Chief Medical Officer and Head of Global Product Development: "At Roche, our goal is to create new possibilities for patients with challenging diseases. We believe bexobrutideg represents a major leap forward in the fight against complex blood cancers and other diseases. We are proud to join forces with Nurix to accelerate these potential breakthroughs."

Summary of Business Terms
Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milestones for potential total payments of up to $2.3 billion. Development costs will be shared 40% by Nurix and 60% by Roche. The parties will equally split the profits and losses from U.S. commercialization. Nurix and Roche will co-commercialize bexobrutideg in the United States across all indications. Outside of the United States, Roche will be responsible for commercialization, with Nurix eligible to receive royalties ranging from the low- to high-teens.

Bexobrutideg (NX-5948)
Bexobrutideg is an investigational, oral, brain penetrant, highly selective small molecule BTK targeted protein degrader. BTK is a central signaling node controlling B cell growth, development and immunologic activity. Unlike conventional BTK inhibitors which block BTK kinase activity, bexobrutideg harnesses the body’s natural protein disposal system (the ubiquitin proteasome pathway) to selectively eliminate BTK protein from cells, removing both the kinase activity of BTK and its scaffolding signaling function. This catalytic degradation-based mechanism offers several potential advantages, including activity against wild-type and mutant forms of BTK that limit the effectiveness of existing BTK inhibitors as well as sustained pharmacodynamic effects at low drug concentrations.

Patients with B-cell–driven malignancies and immune-mediated diseases continue to face significant unmet need despite advances with BTK inhibitors and other therapies. Many patients with CLL ultimately experience disease progression due to acquired resistance mutations, incomplete pathway suppression, or intolerance that limits long-term use, and treatment options remain limited once patients relapse. In early clinical studies, bexobrutideg has demonstrated high overall objective response rates in CLL patients who have progressed on other therapies, including those whose disease has spread to the brain and those with either wild-type BTK protein or acquired resistance mutations to current BTK inhibitors. Together, these attributes offer the potential to expand the therapeutic impact of BTK targeting across B-cell malignancies, with the goal of delivering more meaningful and lasting benefits for patients.

In immunology and neurology, current therapies often require injectable or chronic intravenous administration, may not fully control disease activity, and can be associated with meaningful safety or convenience burdens. Bexobrutideg is designed to address these limitations as an oral treatment that eliminates both the kinase and scaffolding functions of BTK across immune cell types, resulting in more complete and sustained suppression of BTK signaling and offering the potential for improved efficacy and durability in autoimmune disease settings. The high potency and exquisite selectivity of bexobrutideg’s targeted protein degradation mechanism also holds the potential to provide a superior safety and tolerability profile. Bexobrutideg’s high potency is driven by the catalytic nature of its degradation activity, which allows its therapeutic effects to be achieved with significantly lower drug levels in the blood as compared to BTK inhibitors. This lower systemic exposure enhances the potential to provide a more favorable safety profile.

Goldman Sachs & Co. LLC is acting as the exclusive financial advisor to Nurix.

Conference call details

At 8:00 a.m., ET, June 8, 2026, Nurix will host a conference call and webcast to discuss this update. The live webcast, with an accompanying presentation, will be accessible under the Events and Presentations page in the Investors section of the company’s website here. To participate in the live conference call, please follow this link. A replay of the webcast and call will be archived on the Nurix website for approximately 30 days after the event.

(Press release, Nurix Therapeutics, JUN 8, 2026, View Source [SID1234666483])